RICHTER:BETChemical Works of Gedeon Richter Plc Analysis
Data as of 2026-06-22 - not real-time
$31.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: The stock has slipped sharply below recent support, with the short‑term moving average now beneath the market price and the mid‑range RSI indicating neutral momentum. The MACD histogram is negative, signalling bearish pressure, while overall trend metrics suggest a neutral stance amid rising volume.
Fundamental backdrop: Valuation metrics are compelling, with the price‑earnings multiple far under the industry norm and a price‑to‑book ratio that points to deep discounting. The dividend yield is attractive and the payout ratio sits comfortably within cash‑flow capacity, supporting sustainability. Low beta and a defensive healthcare focus temper volatility, though recent price action and high short‑term volatility elevate risk. Material news highlights continued community engagement through the journalism award, but no direct catalyst affecting earnings or pipeline is evident.
Fundamental backdrop: Valuation metrics are compelling, with the price‑earnings multiple far under the industry norm and a price‑to‑book ratio that points to deep discounting. The dividend yield is attractive and the payout ratio sits comfortably within cash‑flow capacity, supporting sustainability. Low beta and a defensive healthcare focus temper volatility, though recent price action and high short‑term volatility elevate risk. Material news highlights continued community engagement through the journalism award, but no direct catalyst affecting earnings or pipeline is evident.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price trading below recent support
- bearish MACD momentum
- elevated short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- significant valuation discount to peers
- strong dividend yield with sustainable payout
- low beta indicating defensive profile
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- stable demand in specialty and generic pharmaceuticals
- strategic collaborations expanding pipeline
- consistent cash generation supporting dividend and growth
Key Metrics & Analysis
Financial Health
Revenue Growth-1.70%
Profit Margin24.80%
P/E Ratio7.4
ROE16.36%
ROA11.03%
Debt/Equity6.86
P/B Ratio0.0
Free Cash Flow$193.1B
Industry P/E24.1
Technical Analysis
TrendNeutral
RSI44.1
Support$37.30
Resistance$43.62
MA 20$39.52
MA 50$40.76
MA 200$33.06
MACDBearish
VolumeIncreasing
Fear & Greed Index91.75
Valuation
Fair Value$13,935.70
GradeUndervalued
TypeValue
Dividend Yield5.50%
Risk Assessment
Beta0.66
Volatility40.37%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.